首页> 外文期刊>Evidence-based complementary and alternative medicine: eCAM >Synergistic Effect of Network-Based Multicomponent Drugs: An Investigation on the Treatment of Non-Small-Cell Lung Cancer with Compound Liuju Formula
【24h】

Synergistic Effect of Network-Based Multicomponent Drugs: An Investigation on the Treatment of Non-Small-Cell Lung Cancer with Compound Liuju Formula

机译:基于网络的多组分药物的协同作用:复合柳埠配方对非小细胞肺癌的研究

获取原文
       

摘要

Lung cancer is the most common cause of cancer death with high morbidity and mortality, which non-small-cell lung cancer (NSCLC) accounting for the majority. Traditional Chinese Medicine (TCM) is effective in the treatment of complex diseases, especially cancer. However, TCM is still in the conceptual stage. The interaction between different components remains unknown due to its multicomponent and multitarget characteristics. In this study, compound Liuju formula was taken as an example to isolate compounds with synergistic biological activity through systems pharmacology strategy. Through pharmacokinetic evaluation, 37 potentially active compounds were screened out. Meanwhile, 116 targets of these compounds were obtained by combing with the target prediction model. Through network analysis, we found that multicomponent drugs can present a synergistic effect through regulating inflammatory signaling pathway, invasion pathway, proliferation, and apoptosis pathway. Finally, it was confirmed that the bioactive compounds of compound Liuju formula have not only a killing effect on NSCLC tumor cells but also a synergistic effect on inhibiting the secretion of correlative inflammatory mediators, including TNF-α and IL-1β. The systems pharmacology method was applied in this study, which provides a new direction for analyzing the mechanism of TCM.
机译:肺癌是癌症死亡的最常见的发病率和死亡率,其中非小细胞肺癌(NSCLC)占多数。中药(TCM)有效地治疗复杂疾病,尤其是癌症。但是,中医仍在概念阶段。由于其多组分和多元特性,不同组件之间的相互作用仍然未知。在该研究中,化合物柳氏配方用作通过系统药理学策略将化合物与协同生物活性分离。通过药代动力学评估,筛选出37个潜在的活性化合物。同时,通过与靶预测模型梳理来获得116个靶标。通过网络分析,我们发现多组分药物可以通过调节炎症信号通路,侵袭途径,增殖和凋亡途径来表现协同效果。最后,证实了化合物柳颈型配方的生物活性化合物不仅对NSCLC肿瘤细胞的杀伤作用而且对抑制相关炎症介质的分泌,包括TNF-α和IL-1β的协同作用。在该研究中应用了系统药理学方法,提供了分析中医机制的新方向。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号